274 related articles for article (PubMed ID: 22027908)
1. Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study.
Robinson DW; Cormier JN; Zhao N; Uhlar CM; Revicki DA; Cella D
Melanoma Res; 2012 Feb; 22(1):54-62. PubMed ID: 22027908
[TBL] [Abstract][Full Text] [Related]
2. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).
Ziefle S; Egberts F; Heinze S; Volkenandt M; Schmid-Wendtner M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Heinz A; Hauschild A; Schaefer M
J Immunother; 2011 May; 34(4):403-8. PubMed ID: 21499123
[TBL] [Abstract][Full Text] [Related]
4. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
Long GV; Atkinson V; Ascierto PA; Robert C; Hassel JC; Rutkowski P; Savage KJ; Taylor F; Coon C; Gilloteau I; Dastani HB; Waxman IM; Abernethy AP
Ann Oncol; 2016 Oct; 27(10):1940-6. PubMed ID: 27405322
[TBL] [Abstract][Full Text] [Related]
5. Measurement of health-related quality of life with glaucoma: validation of the Glau-QoL 36-item questionnaire.
Béchetoille A; Arnould B; Bron A; Baudouin C; Renard JP; Sellem E; Brouquet Y; Denis P; Nordmann JP; Rigeade MC; Bassols A; Benmedjahed K; Guillemin I; Rouland JF
Acta Ophthalmol; 2008 Feb; 86(1):71-80. PubMed ID: 17725614
[TBL] [Abstract][Full Text] [Related]
6. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
Eigentler TK; Weide B; de Braud F; Spitaleri G; Romanini A; Pflugfelder A; González-Iglesias R; Tasciotti A; Giovannoni L; Schwager K; Lovato V; Kaspar M; Trachsel E; Menssen HD; Neri D; Garbe C
Clin Cancer Res; 2011 Dec; 17(24):7732-42. PubMed ID: 22028492
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
8. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
9. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
11. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
Weber JS; Samlowski WE; Gonzalez R; Ribas A; Stephenson J; O'Day S; Sato T; Dorr R; Grenier K; Hersh E
Cancer; 2010 Aug; 116(15):3683-91. PubMed ID: 20564083
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen.
Cocconi G; Bella M; Calabresi F; Tonato M; Canaletti R; Boni C; Buzzi F; Ceci G; Corgna E; Costa P
N Engl J Med; 1992 Aug; 327(8):516-23. PubMed ID: 1635566
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
Hersey P; Sosman J; O'Day S; Richards J; Bedikian A; Gonzalez R; Sharfman W; Weber R; Logan T; Buzoianu M; Hammershaimb L; Kirkwood JM;
Cancer; 2010 Mar; 116(6):1526-34. PubMed ID: 20108344
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.
Trask PC; Bushmakin AG; Cappelleri JC; Bycott P; Liau K; Kim S
Acta Oncol; 2008; 47(5):843-51. PubMed ID: 18568482
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial.
Hofmann MA; Hauschild A; Mohr P; Garbe C; Weichenthal M; Trefzer U; Drecoll U; Tilgen W; Schadendorf D; Kaatz M; Ulrich J
Melanoma Res; 2011 Dec; 21(6):516-23. PubMed ID: 22076216
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
18. Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with atrial fibrillation (AF-QoL).
Badia X; Arribas F; Ormaetxe JM; Peinado R; de Los Terreros MS
Health Qual Life Outcomes; 2007 Jul; 5():37. PubMed ID: 17610734
[TBL] [Abstract][Full Text] [Related]
19. A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.
O'Day S; Pavlick A; Loquai C; Lawson D; Gutzmer R; Richards J; Schadendorf D; Thompson JA; Gonzalez R; Trefzer U; Mohr P; Ottensmeier C; Chao D; Zhong B; de Boer CJ; Uhlar C; Marshall D; Gore ME; Lang Z; Hait W; Ho P;
Br J Cancer; 2011 Jul; 105(3):346-52. PubMed ID: 21750555
[TBL] [Abstract][Full Text] [Related]
20. Assessing the psychometric characteristics of the Macedonian version of the Oral Health Impact Profile questionnaire (OHIP-MAC49).
Kenig N; Nikolovska J
Oral Health Dent Manag; 2012 Mar; 11(1):29-38. PubMed ID: 22488030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
